May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration: 12 Months Results
Author Affiliations & Notes
  • B. Voykov
    Center for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • F. Ziemssen
    Center for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • M. Voelker
    Center for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • W. Inhoffen
    Center for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • K. U. Bartz-Schmidt
    Center for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • F. Gelisken
    Center for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Footnotes
    Commercial Relationships  B. Voykov, None; F. Ziemssen, None; M. Voelker, None; W. Inhoffen, None; K.U. Bartz-Schmidt, None; F. Gelisken, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 275. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B. Voykov, F. Ziemssen, M. Voelker, W. Inhoffen, K. U. Bartz-Schmidt, F. Gelisken; Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration: 12 Months Results. Invest. Ophthalmol. Vis. Sci. 2008;49(13):275. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the 12 months results of intravitreal bevacizumab treatment of neovascular age-related macular degeneration.

Methods: : Retrospective, noncomparative, interventional case series of 125 consecutive patients (126 eyes) that underwent intravitreal bevacizumab treatment for subfoveal choroidal neovascularization by age-related macular degeneration was evaluated. Best corrected visual acuity (BCVA) was assessed at baseline and 12 month follow-up.

Results: : Mean BCVA was 20/81 at baseline and 20/111 at 12 month follow-up (p=0.003). In 70.6% (89/126) of the eyes, BCVA showed less than 3 lines worsening from baseline. Mean BCVA improved 1 or more lines in 33.9% (44/126) of the eyes and 3 or more lines in 13.5% (13/126) of the eyes. Six eyes developed retinal pigment epithelial tears. No endophthalmitis, retinal detachment or systemic side effects were seen.

Conclusions: : Intravitreal bevacizumab injections can prevent vision loss in the majority of eyes with subfoveal neovascular age-related macular degeneration. One third of the eyes showed a vision improvement at 12 months. Larger controlled clinical trials are warranted to evaluate the effect of intravitreal bevacizumab therapy in neovascular age-related macular degeneration.

Keywords: age-related macular degeneration • visual acuity • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×